prostatepedia magazine covers


Prostatepedia features informal conversations with doctors, patients, and activists about prostate cancer about prostate cancer. Each month they tackle a different topic facing prostate cancer patients today—from how imaging has impacted treatment to dealing with erectile dysfunction after radiation or surgery to the evolving field of immunotherapy.

Prostatepedia Magazine (quarterly) and the weekly Prostatepedia Digests became part of NASPCC starting with the August 2020 issue.

Use this link to learn more about Prostatepedia...

 “Innovations in Prostate Cancer Care”

with Eric Klein, MD

NEW DATE - Thursday, September 29, 2022
7:00 pm – 8:00 pm EASTERN / 4:00 pm – 5:00 pm PACIFIC

eric klein xThis Webinar will help patients have better shared decision-making with their physicians.

Dr. Klein is the Emeritus Distinguished Professor and Chair of the Glickman Urological and Kidney Institute and Lerner College of Medicine at the Cleveland Clinic. A former President of the Society of Urologic Oncology, Dr. Klein is currently a Fellow in the Distinguished Careers Institute at Stanford University. His clinical and research interests cover all stages of prostate cancer, with a specific interest in genomics and clinical trials. Along with over 700 articles Dr. Klein has authored in the literature as well as 8 books he has either authored or edited; he currently also serves as the Editor-in-Chief of UROLOGY. Dr. Eric Klein’s awards are too numerous to list in this Flyer, but he is beloved by patients and by colleagues as well.

Use this link to register for the September 29, 2022 webinar

Use this link to download the September 29, 2022 webinar flyer - PDF


“Epigenetic Control of Cancer Immunity”

Dr. Leigh EllisWith Leigh Ellis, PhD

This event has been POSTPONED and will be Rescheduled at a later date.

Dr. Leigh Ellis, Scientific Director of the Center for Urologic Research Excellence and Associate Professor, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center

The Ellis laboratory’s focus is the discovery of how a prostate cancer cell controls the expression of genes (epigenetics) to drive metastasis and resistance to current therapies. Their work has demonstrated how the epigenetic regulator, EZH2, controls prostate cell fidelity and evasion of immune detection, and has shown that inhibition of EZH2 resulted in reprogramming both the prostate tumor and its tumor microenvironment to re-sensitize to androgen deprivation therapy and check-point immunotherapy.

Please also check out our Archived Webinars...

Please use this link to view NASPCC's archived webinars...

rev: 03/04/2022